DR3:TL1A Inhibitor Screening Assay Kit workflow diagram. First, DR3 is coated on a 96-well or 384-wellplate. Next, biotinylated TL1A is incubated with DR3. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence. The chemiluminescence signal is proportional to the binding of DR3:TL1A
DR3:TL1A Inhibitor Screening Assay Kit workflow diagram. First, DR3 is coated on a 96-well or 384-wellplate. Next, biotinylated TL1A is incubated with DR3. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence. The chemiluminescence signal is proportional to the binding of DR3:TL1A
DR3:TL1A Inhibitor Screening Assay Kit
82241
Product group Assays
Overview
- SupplierBPS Bioscience
- Product NameDR3:TL1A Inhibitor Screening Assay Kit
- Delivery Days Customer7
- CertificationResearch Use Only
- Scientific DescriptionThe DR3:TL1A Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of the interaction between DR3 (Death Receptor 3) and TL1A (TNF-like ligand 1A). This kit comes in a convenient 96-well or 384-well format, with biotin-labeled TL1A, purified DR3, streptavidin-labeled HRP, and assay buffer for 100 or 400 binding reactions.
- Storage InstructionSee Manual
- UNSPSC41116133